 |
|
Angioneurotic Edema Attributed to the Use of Losartan
Era W. van Rijnsoever, PharmD;
Wilma J. M. Kwee-Zuiderwijk, PharmD;
Johannes Feenstra, MD
Arch Intern Med. 1998;158:2063-2065.
Background Angioedema is a well-known adverse effect of angiotensin-converting enzyme inhibitors.The bradykinin accumulation as a result of the decreased degradation of bradykinin is thought to be the causal mechanism. Angiotensin II antagonists seem to have no effect on the degradation of bradykinin. Therefore, it was expected that angioedema would not occur during treatment with losartan potassium, the first orally active angiotensin II antagonist.
Methods We reviewed the 13 case reports of angioedema associated with the use of losartan reported to Lareb (Netherlands Pharmacovigilance Foundation, Den Bosch) and to the Drug Safety Unit of the Inspectorate for Health Care, Ryswyh, in the Netherlands since the introduction of losartan in 1995 until May 1997.
Results In all 13 cases, a diagnosis of angioedema attributed to the use of losartan seems to be very plausible. In 7 cases the diagnosis could not be confirmed by a physician because the symptoms had already been resolved, but the signs and symptoms clearly indicated angioedema. The adverse reactions occurred within 24 hours to 16 months after the initiation of losartan therapy. Three patients had previously experienced angioedema during treatment with an angiotensin-converting enzyme inhibitor. Eleven of the patients involved were women and 2 were men.
Conclusions Our observations strongly suggest that the onset of angioedema was associated with the use of losartan. Physicians and pharmacists should be aware of this potentially life-threatening complication. It may be advisable not to prescribe angiotensin II antagonists to patients with a history of angioedema (of whatever origin).
From Pharmacy Apotheek Leusden, Leusden (Dr van Rijnsoever), the Netherlands Pharmacovigilance Foundation, Den Bosch (Dr Kwee-Zuiderwijk), the Drug Safety Unit of the Inspectorate for Health Care, Ryswyh (Dr Feenstra), and the Department of Epidemiology and Biostatistics, Erasmus University Medical School, Rotterdam (Dr Feenstra), the Netherlands.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Angioedema Associated With Angiotensin-Converting Enzyme Inhibitor Use: Outcome After Switching to a Different Treatment
Cicardi et al.
Arch Intern Med 2004;164:910-913.
ABSTRACT
| FULL TEXT
ORAL ADVERSE DRUG REACTIONS TO CARDIOVASCULAR DRUGS
Torpet et al.
CROBM 2004;15:28-46.
ABSTRACT
| FULL TEXT
Valsartan-Induced Angioedema
Irons and Kumar
The Annals of Pharmacotherapy 2003;37:1024-1027.
ABSTRACT
| FULL TEXT
Literature Reports of Angiotensin Receptor Antagonist-Induced Angioedema in Patients With a History of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema
Flais
Arch Intern Med 2003;163:1488-1488.
FULL TEXT
Angioedema and AT1 Receptor Blockers: Proceed With Caution
MacLean and Hannaway
Arch Intern Med 2003;163:1488-1489.
FULL TEXT
Review: The pharmacokinetics and pharmacodynamics of angiotensin-receptor blockers in end-stage renal disease
Sica and Gehr
Journal of Renin-Angiotensin-Aldosterone System 2002;3:247-254.
ABSTRACT
The Role of Angiotensin Receptor Blockers in the Management of Chronic Heart Failure
Jamali et al.
Arch Intern Med 2001;161:667-672.
ABSTRACT
| FULL TEXT
Angiotensin II Type 1 Receptor Blockers
Burnier
Circulation 2001;103:904-912.
FULL TEXT
Are Angiotensin II Receptor Antagonists Safe in Patients With Previous Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema?
Fuchs et al.
Hypertension 2001;e1: -e1.
FULL TEXT
Angiotensin II Receptor Blockers: Equal or Preferred Substitutes for ACE Inhibitors?
Grossman et al.
Arch Intern Med 2000;160:1905-1911.
FULL TEXT
Nitric oxide mediates inhibitory effect of losartan on angiotensin-induced contractions in hamster but not rat aorta
Inoue et al.
Journal of Renin-Angiotensin-Aldosterone System 2000;1:180-183.
ABSTRACT
|
